Literature DB >> 24207125

Transient protein states in designing inhibitors of the MDM2-p53 interaction.

Michal Bista1, Siglinde Wolf, Kareem Khoury, Kaja Kowalska, Yijun Huang, Ewa Wrona, Marcelino Arciniega, Grzegorz M Popowicz, Tad A Holak, Alexander Dömling.   

Abstract

Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an efficient, nongenotoxic approach to a wide variety of cancers. We present the cocrystal structures of two complexes of MDM2 with inhibitors based on 6-chloroindole scaffolds. Both molecules bound to a distinct conformational state of MDM2 with nM-μM affinities. In contrast to other structurally characterized antagonists, which mimic three amino acids of p53 (Phe19, Trp23, and Leu26), the compounds induced an additional hydrophobic pocket on the MDM2 surface and unveiled a four-point binding mode. The enlarged interaction interface of the inhibitors resulted in extension of small molecules binding toward the "lid" segment of MDM2 (residues 19-23)--a nascent element that interferes with p53 binding. As supported by protein engineering and molecular dynamics studies, employing these unstable elements of MDM2 provides an efficient and yet unexplored alternative in development of MDM2-p53 association inhibitors.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24207125      PMCID: PMC4104591          DOI: 10.1016/j.str.2013.09.006

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  49 in total

1.  Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Authors:  Yijun Huang; Siglinde Wolf; David Koes; Grzegorz M Popowicz; Carlos J Camacho; Tad A Holak; Alexander Dömling
Journal:  ChemMedChem       Date:  2011-09-27       Impact factor: 3.466

Review 2.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

3.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.

Authors:  Grzegorz M Popowicz; Anna Czarna; Tad A Holak
Journal:  Cell Cycle       Date:  2008-05-27       Impact factor: 4.534

4.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.

Authors:  Anna Czarna; Grzegorz M Popowicz; Aleksandra Pecak; Siglinde Wolf; Grzegorz Dubin; Tad A Holak
Journal:  Cell Cycle       Date:  2009-04-16       Impact factor: 4.534

Review 5.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

6.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

Review 7.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

8.  Robust NMR screening for lead compounds using tryptophan-containing proteins.

Authors:  Michal Bista; Kaja Kowalska; Weronika Janczyk; Alexander Dömling; Tad A Holak
Journal:  J Am Chem Soc       Date:  2009-06-10       Impact factor: 15.419

9.  Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors.

Authors:  Yujun Zhao; Liu Liu; Wei Sun; Jianfeng Lu; Donna McEachern; Xiaoqin Li; Shanghai Yu; Denzil Bernard; Philippe Ochsenbein; Vincent Ferey; Jean-Christophe Carry; Jeffrey R Deschamps; Duxin Sun; Shaomeng Wang
Journal:  J Am Chem Soc       Date:  2013-05-03       Impact factor: 15.419

10.  Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.

Authors:  Yong S Chang; Bradford Graves; Vincent Guerlavais; Christian Tovar; Kathryn Packman; Kwong-Him To; Karen A Olson; Kamala Kesavan; Pranoti Gangurde; Aditi Mukherjee; Theresa Baker; Krzysztof Darlak; Carl Elkin; Zoran Filipovic; Farooq Z Qureshi; Hongliang Cai; Pamela Berry; Eric Feyfant; Xiangguo E Shi; James Horstick; D Allen Annis; Anthony M Manning; Nader Fotouhi; Huw Nash; Lyubomir T Vassilev; Tomi K Sawyer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-14       Impact factor: 11.205

View more
  21 in total

1.  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.

Authors:  Constantinos G Neochoritis; Jack Atmaj; Aleksandra Twarda-Clapa; Ewa Surmiak; Lukasz Skalniak; Lisa-Maria Köhler; Damian Muszak; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Barbara Beck; Tad A Holak; Alexander Dömling
Journal:  Eur J Med Chem       Date:  2019-08-06       Impact factor: 6.514

2.  A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells.

Authors:  Lukasz Skalniak; Aleksandra Twarda-Clapa; Constantinos G Neochoritis; Ewa Surmiak; Monika Machula; Aneta Wisniewska; Beata Labuzek; Ameena M Ali; Sylwia Krzanik; Grzegorz Dubin; Matthew Groves; Alexander Dömling; Tad A Holak
Journal:  FEBS J       Date:  2019-02-16       Impact factor: 5.542

Review 3.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

4.  Co-operative intra-protein structural response due to protein-protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding.

Authors:  Sudipta Samanta; Sanchita Mukherjee
Journal:  J Comput Aided Mol Des       Date:  2017-09-04       Impact factor: 3.686

5.  Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Authors:  S Shaabani; C G Neochoritis; A Twarda-Clapa; B Musielak; T A Holak; A Dömling
Journal:  Medchemcomm       Date:  2017-03-15       Impact factor: 3.597

6.  Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.

Authors:  Sachin P Patil; Michael F Pacitti; Kevin S Gilroy; John C Ruggiero; Jonathan D Griffin; Joseph J Butera; Joseph M Notarfrancesco; Shawn Tran; John W Stoddart
Journal:  J Comput Aided Mol Des       Date:  2014-11-07       Impact factor: 3.686

Review 7.  Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

Authors:  Murali Munisamy; Nayonika Mukherjee; Levin Thomas; Amy Trinh Pham; Arash Shakeri; Yusheng Zhao; Jill Kolesar; Praveen P N Rao; Vivek M Rangnekar; Mahadev Rao
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

8.  Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.

Authors:  Edwin Kroon; Jörg O Schulze; Evelyn Süß; Carlos J Camacho; Ricardo M Biondi; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2015-09-04       Impact factor: 15.336

Review 9.  How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Alexander Dömling
Journal:  ChemMedChem       Date:  2015-12-16       Impact factor: 3.466

10.  2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.

Authors:  Constantinos G Neochoritis; Kan Wang; Natalia Estrada-Ortiz; Eberhardt Herdtweck; Katarzyna Kubica; Aleksandra Twarda; Krzysztof M Zak; Tad A Holak; Alexander Dömling
Journal:  Bioorg Med Chem Lett       Date:  2015-12-15       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.